跳至主要内容
临床试验/NCT04327713
NCT04327713Unknown不适用

Systematic Review and Meta-analysis of Randomized Controlled Trials of the Effect of Fish Oil Supplementation on Cardiovascular Outcomes in Diabetes

University of Toronto1 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2020年3月28日最近更新:
适应症

试验速览

阶段
不适用
入组人数
1
试验地点
1
主要终点
Total cardiovascular disease (CVD) incidence

研究概览

简要总结

Fish oil contains a large amount of long-chain omega-3 polyunsaturated fatty acids, which are considered an important component of a healthy diet. As many patients do not eat fish, supplementation with fish oil is a common strategy to provide sufficient amounts of these particular fatty acids in daily life. Fish oil supplementation has been investigated for decades for its cardio-protective effects and its ability to lower serum triglycerides. People with diabetes mellitus have an increased risk for cardiovascular events and show alterations in lipids with high triglycerides. Whether there is a benefit of fish oil supplementation in this high risk group remains unclear with major international diabetes associations recommending against the use of fish oil supplements. The European Association for the Study of Diabetes (EASD) has not made any recommendations about the use of fish oils in people with diabetes since 2004. To inform the update of the EASD clinical practice guidelines for nutrition therapy, the Diabetes and Nutrition Study Group (DNSG) of the EASD has commissioned the proposed systematic review and meta-analysis of randomized controlled trials of the effect of fish oil supplementation on cardiovascular outcomes in people with diabetes and use the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess the certainty of the evidence.

详细描述

Background: Cardiovascular disease (CVD) accounts for a large proportion of annual deaths around the world. In both the general population as well as in high-risk subgroups, achieving a healthy diet is one approach to lower the risk for CVD. Fish oil supplements have been widely investigated for cardiovascular indications, showing consistent reductions in triglycerides with variable effects on other intermediate risk factors (glycemia, blood pressure, inflammation) which have not translated into reductions in patient-important clinical outcomes. Recent systematic reviews and meta-analyses of the available randomized trials have failed to show a meaningful cardiovascular benefit of fish oil supplementation. It is unclear whether this lack of benefit holds across all groups, especially groups with a high triglyceride phenotype and at high cardiovascular risk such as those with diabetes. No systematic review and meta-analysis has specifically synthesized the evidence of the effect of fish oil supplementation on cardiovascular outcomes in people with diabetes. On the basis of several recent large cardiovascular outcomes trials in people with diabetes or that included subgroups of people with diabetes, the 2019 American Diabetes Association and 2018 Diabetes Canada clinical practice guidelines recommended against the use of fish oil supplementation for cardiovascular risk reduction in people with diabetes. The European Association for the Study of Diabetes (EASD) have made a similar recommendation but have not updated their clinical practice guidelines since 2004. To inform the update of the EASD clinical practice guidelines for nutrition therapy, the Diabetes and Nutrition Study Group (DNSG) of the EASD has commissioned a series of evidence syntheses. The proposed systematic review and meta-analysis of randomized controlled trials will assess the effect of fish oil supplementation on cardiovascular outcomes in people with diabetes and use the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess the certainty of the evidence.

Need for proposed research: There is an urgent need for a synthesis of the evidence of the effect of fish oil supplementation on cardiovascular outcomes in people with diabetes to inform the update of the EASD clinical practice guidelines for nutrition therapy. High quality systematic reviews and meta-analyses of randomized controlled trials with assessment of the certainty of the evidence using GRADE provide the strongest form of evidence synthesis to support clinical practice guidelines and public health policy development.

Objective: To inform the update of the European Association for the Study of Diabetes (EASD) clinical practice guidelines for nutrition therapy, the investigators will conduct a systematic review and meta-analysis of randomized controlled trials of the effect of fish oil supplementation on cardiovascular outcomes in people with diabetes and use the GRADE approach to assess the certainty of the evidence.

Design: The planning and conduct of the proposed meta-analyses will follow the Cochrane handbook for systematic reviews of interventions. The reporting will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Data sources: MEDLINE, EMBASE, and The Cochrane Central Register of Controlled Trials databases will be searched using appropriate search terms supplemented by hand searches of references of included studies.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Randomized controlled trials
  • Participants with diabetes
  • Follow-up duration ≥ 52 weeks
  • Intervention involves fish oil supplementation using supplements, supplemented foods, or dietary advice
  • Control group
  • Ascertainment of at least one cardiovascular outcome

排除标准

  • Non-randomized studies
  • Participants without diabetes
  • Follow-up duration <52 weeks
  • Multi-modal interventions
  • Interventions of fish oils in the form of a prescription pharmaceutical drug (e.g. icosapent ethyl)
  • Lack of a suitable control group (e.g. fish oil containing comparator)
  • No viable cardiovascular outcome data.

结局指标

主要结局

Total cardiovascular disease (CVD) incidence

时间窗: at least 1 year

Risk ratio of fatal and non-fatal CVD events

次要结局

  • CVD mortality(at least 1 year)
  • All-cause mortality(at least 1 year)
  • Coronary heart disease (CHD) incidence(at least 1 year)
  • Major adverse cardiovascular events (MACE)(at least 1 year)
  • Coronary heart disease (CHD) mortality(at least 1 year)
  • Myocardial infarction (MI) incidence(at least 1 year)
  • Stroke incidence(at least 1 year)
  • Arrhythmia incidence(at least 1 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

John Sievenpiper

Associate Professor

University of Toronto

研究点 (1)

Loading locations...

相似试验